EVITA - Epcoritamab plus Venetoclax plus Ibrutinib in patients with chronic lymphocytic leukemia with TP53 Alterations

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520893-20-00

Enrollment

Registered

2026-10-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic lymphocytic leukemia, B-cell small lymphocytic lymphoma

Brief summary

Complete remission (CR) rate AND undetectable minimal residual disease (uMRD)

Detailed description

undetectable MRD (uM), Complete Remission Rate (CRR), Overall Response Rate (ORR), Duration of Response (DoR), Duration of Complete Response (DoCR), Time to Next Treatment (TTNT), Peripheral blood MRD, Progression Free Survival (PFS), Overall Survival (OS), Incidence and severity of AEs including SAEs and AESIs

Interventions

DRUGVenetoclax

DRUGEpcoritamab (GEN3013)

DRUGIBRUTINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Complete remission (CR) rate AND undetectable minimal residual disease (uMRD)	—

Secondary

Measure	Time frame
undetectable MRD (uM), Complete Remission Rate (CRR), Overall Response Rate (ORR), Duration of Response (DoR), Duration of Complete Response (DoCR), Time to Next Treatment (TTNT), Peripheral blood MRD, Progression Free Survival (PFS), Overall Survival (OS), Incidence and severity of AEs including SAEs and AESIs	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 17, 2026